Welcome to our dedicated page for Scholar Rock Holding SEC filings (Ticker: SRRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Scholar Rock Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Scholar Rock Holding's regulatory disclosures and financial reporting.
Scholar Rock Holding Corporation received an updated Schedule 13G/A from investment manager Redmile Group, LLC, individual filer Jeremy C. Green, and RedCo II Master Fund, L.P.. Redmile and Green report beneficial ownership of 4,311,092 shares of Scholar Rock common stock, representing 3.6% of the class.
All 4,311,092 shares are held by investment vehicles managed by Redmile, and both Redmile and Green report shared voting and dispositive power over these shares, with no sole voting or dispositive power. The ownership percentage is based on 119,828,338 shares outstanding as of May 4, 2026. RedCo II Master Fund, L.P. reports 0 shares and 0.0% ownership. Redmile and Green each disclaim beneficial ownership except to the extent of their pecuniary interest.
Scholar Rock Holding Corporation received an amended Schedule 13G filing showing that Invus Public Equities, L.P. and related entities collectively report beneficial ownership of 9,575,013 shares of common stock. Based on 119,828,338 shares outstanding as of May 4, 2026, this represents 8.0% of Scholar Rock’s common stock. The Invus structure runs through Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., and ultimately to Raymond Debbane, each of whom may be deemed to beneficially own the same block of shares through their control relationships. The reporting group states the shares were not acquired for the purpose of changing or influencing control of Scholar Rock, consistent with passive investment status under Schedule 13G.
Scholar Rock Holding Corporation described an update to its existing at-the-market offering program. The company filed a new prospectus supplement under its shelf registration statement on Form S-3ASR, allowing it to offer and sell, from time to time at its sole discretion through Jefferies LLC as sales agent, additional shares of common stock with an aggregate offering price of up to $200,000,000.
This new prospectus supplement replaces and supersedes the prior prospectus supplement dated November 14, 2025, and the offering pursuant to that prior supplement has been terminated. To date, the company has generated approximately $257.7 million in net proceeds from sales of common stock under the at-the-market program. Legal opinions and related consents from Goodwin Procter LLP are included as exhibits.
Scholar Rock Holding Corporation is adding capacity under its existing Open Market Sale agreement with Jefferies LLC to sell up to $200,000,000 of common stock in an at-the-market offering. This prospectus supplement resets the remaining availability under the sales agreement to $200,000,000 and replaces a prior supplement.
Sales will be made from time to time through Jefferies, acting as sales agent, with compensation of up to 3.0% of gross proceeds. The company had 121,600,396 shares outstanding as of June 30, 2026; an illustrative scenario assumes 4,362,050 shares sold at $45.85 per share. After such sales, adjusted net tangible book value would rise from $2.09 to $3.55 per share, implying dilution of $42.30 per share to new investors.
Net proceeds, together with existing cash, cash equivalents and investments, are intended to support commercialization of apitegromab, advance ongoing and future clinical programs, further develop the company’s TGFβ-based platform and pipeline, and for working capital and general corporate purposes. Scholar Rock is a late-stage biopharmaceutical company focused on neuromuscular diseases; its lead antibody apitegromab for spinal muscular atrophy has a resubmitted BLA under FDA priority review with a September 30, 2026 PDUFA action date and an MAA under review in Europe.
Scholar Rock Holding Corporation is a biopharmaceutical company focused on spinal muscular atrophy (SMA) and other rare neuromuscular diseases. Its lead antibody, apitegromab, has positive Phase 3 SAPPHIRE data in non‑ambulatory Type 2/3 SMA, and a resubmitted Biologics License Application was accepted by the FDA with a September 30, 2026 PDUFA action date. A marketing authorization application for SMA is also under review in Europe.
For the six months ended June 30, 2026, the company reported a net loss of $215.4 million, driven by research and development expense of $110.0 million and general and administrative expense of $100.9 million as it builds commercial infrastructure. Cash, cash equivalents and marketable securities totaled $492,088 (thousands), and management expects this to fund operations into the second half of 2027.
During 2026, Scholar Rock strengthened its balance sheet through a new term loan facility with Blue Owl, drawing $200.0 million, and via an at‑the‑market equity program that raised $160.8 million. Key programs include the ONYX long‑term extension in SMA, Phase 2 OPAL in SMA patients under age two, Phase 2 FORGE in FSHD, and a Phase 1 study of SRK‑439.
Scholar Rock reported a Q2 2026 net loss of $109.9 million, or $0.84 per share, with no revenue for the quarter. Research and development expense was $58.2 million and general and administrative expense was $50.7 million. The company ended June 30, 2026 with $492.1 million in cash, cash equivalents, and marketable securities, reflecting $62.8 million of net proceeds from its at-the-market equity program.
The company highlighted regulatory progress for its lead SMA candidate apitegromab. Its Biologics License Application is under FDA review with a September 30, 2026 PDUFA date, supported by two fill-finish facilities and what the company describes as ample commercial supply upon approval. The EMA is reviewing a Marketing Authorisation Application and is awaiting FDA inspection classification of the Catalent Indiana facility, while Scholar Rock discusses adding a second fill-finish site. The U.S. commercial team is preparing for launch, and development continues in earlier-stage programs, including the Phase 2 OPAL trial in infants and toddlers with SMA, the newly initiated Phase 2 FORGE trial in FSHD, and a Phase 1 study of SRK-439 in healthy volunteers.
Scholar Rock Holding Corp director Jeffrey S. Flier reported open-market sales of 3,053 shares of Common Stock on July 1, 2026. The trades were executed at weighted average prices between about $52.96 and $55.01 per share under a pre-arranged Rule 10b-5-1 trading plan to cover tax obligations tied to vesting and settlement of restricted stock units. Following these transactions, the filing reports holdings consisting of 21,017 shares of common stock and 6,839 RSUs, indicating he retains a meaningful equity position in the company.
Scholar Rock Holding Corp director Michael Gilman sold 2,544 shares of common stock in open-market transactions on July 1, 2026. The sales were made under a Rule 10b-5-1 trading plan adopted on March 31, 2026 to cover tax obligations from vesting restricted stock units.
Prices ranged from about $52.97 to $55.01, reported as weighted average prices for each trade. After these transactions, Gilman holds 52,672 shares of common stock and 6,839 restricted stock units (RSUs), indicating he retains a substantial equity position in the company.
Scholar Rock Holding Corp director Kristina Burow reported routine insider sales tied to equity compensation. On July 1, 2026, she sold a total of 3,053 shares of common stock in open-market transactions at weighted average prices around $53–$54 per share. According to the filing, these trades were executed under a Rule 10b-5-1 trading plan adopted on March 31, 2026 to cover tax obligations from the vesting and settlement of restricted stock units (RSUs). After these transactions, she continues to hold 107,818 shares of common stock and 6,839 RSUs directly, and has an indirect interest in 2,345,711 shares held by ARCH Venture Fund VIII, L.P., over which she does not have voting or investment control and for which she disclaims beneficial ownership beyond any pecuniary interest.
Scholar Rock Holding Corp director Joshua Reed sold 3,053 shares of common stock in open-market transactions. The sales on July 1, 2026 were executed at weighted average prices of $53.4958 and $54.2814 per share under a pre-arranged Rule 10b5-1 trading plan. The filing notes the plan was adopted to cover tax obligations tied to the vesting and settlement of restricted stock units, indicating these are largely tax-related, scheduled sales. Following the transactions, Reed holds 19,518 equity-linked units, consisting of 12,679 shares of common stock and 6,839 RSUs.